Supply Chain Integrity Under Fire: Pharmsource Denies Knowledge of Stolen, Recalled Dexcom G7 Sensors

June 20, 2026

Investing.com 南アフリカ

Overview

Pharmaceutical wholesaler Pharmsource LLC denies knowing that Dexcom G7 continuous glucose monitoring (CGM) sensors it acquired were stolen post-disposal and resold, despite being originally slated for destruction. Dexcom had previously warned about these specific sensor lots due to heightened risks of skin infection and inaccurate glucose readings. This incident critically exposes vulnerabilities in medical device supply chain security, highlighting the urgent need for enhanced product tracking and integrity measures to safeguard patient health.

In Depth

Background

The medical device industry operates under stringent demands for quality control and robust supply chain security, spanning from manufacturing and distribution to ultimate disposal. This is particularly critical for high-value devices that directly impact patient health and safety. The secure management and tracking of products, especially those designated for disposal, are paramount to maintaining product integrity and preventing risks to patients.

The Incident

Pharmaceutical wholesaler Pharmsource LLC has issued a statement asserting its lack of knowledge regarding Dexcom G7 continuous glucose monitoring (CGM) sensors that were acquired by the company. These sensors, it was later revealed, were stolen during their disposal process and subsequently resold by a third party, despite being originally designated for destruction. Pharmsource maintains it obtained the sensors through legitimate channels and was not privy to information about their intended destruction. This incident critically underscores potential vulnerabilities within the medical device supply chain, where products intended for permanent removal can illicitly re-enter the market.

Technical and Clinical Implications

In May, Dexcom had previously issued a warning concerning specific lots of its G7 CGM sensors, citing a heightened risk of skin infection and a strong likelihood of inaccurate or absent glucose readings. CGM devices are indispensable tools for individuals with diabetes, providing continuous glucose monitoring essential for informed treatment decisions and effective disease management. The circulation of medical devices that deliver erroneous data or carry infection risks directly jeopardizes patient well-being, potentially leading to delayed or inappropriate treatment. The re-entry of these compromised sensors into the market poses significant, direct risks to patient health and safety.

Strategic Significance & Outlook

This event highlights an urgent need for medical device manufacturers, wholesalers, and regulatory bodies to collaborate on strengthening measures to prevent product diversion and illicit resale. In response, Dexcom and other CGM manufacturers are expected to re-evaluate and enhance their product disposal procedures and overall supply chain security protocols. Wholesalers are likely to face increased scrutiny and pressure to intensify their due diligence regarding the origin and condition of products they acquire. Regulatory agencies may also explore stricter oversight and regulations to combat illicit medical device distribution. Consequently, the industry is anticipated to accelerate its efforts towards building a more secure and trustworthy medical device supply chain, aiming to minimize risks to patients and preserve the integrity of healthcare technologies globally.

Source: https://za.investing.com/news/stock-market-news/pharmsource-says-it-was-unaware-dexcom-sensors-were-stolen-93CH-4323510

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.